RCM
ALXN

RNC Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

RNC Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19,605
Closed -$3.6M – 186
2021
Q2 		$3.6M Buy
19,605
+445
+2% +$76.4K 0.19% 75
2021
Q1 		$2.93M Sell
19,160
-2,759
-13% -$427K 0.17% 79
2020
Q4 		$3.42M Buy
21,919
+86
+0.4% +$11.1K 0.21% 74
2020
Q3 		$2.5M Buy
21,833
+430
+2% +$46.4K 0.18% 70
2020
Q2 		$2.4M Sell
21,403
-929
-4% -$98.6K 0.17% 69
2020
Q1 		$2M Buy
22,332
+190
+0.9% +$18.6K 0.17% 67
2019
Q4 		$2.4M Buy
22,142
+2,685
+14% +$287K 0.15% 76
2019
Q3 		$1.91M Buy
+19,457
New +$2.19M 0.14% 75

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

RNC Capital Management's ALXN Position: Q3 2021 in Review

RNC Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 19,605 shares — an estimated $3.6M sold.

RNC Capital Management first reported a position in ALXN in Q3 2019 and held it in 8 quarters. The position peaked at $3.6M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • RNC Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • RNC Capital Management sold 19,605 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.6M.
  • RNC Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 8 quarters.
  • RNC Capital Management's Alexion Pharmaceuticals position peaked at $3.6M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on RNC Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.